Factors Indicating Need for Dose Escalation Increase doses when minimal subjective improvements after 3-4 weeks at current dose, IGF-1 levels show minimal or no meaningful increase from baseline after an adequate trial period (e.g., 812 weeks), good tolerance without significant side effects suggesting room for higher dosing, and treatment goals require more aggressive approach than current dose provides
Importantly, the recommendations also stress the need for early intervention with combination therapy in high-risk individuals
On the importance of selenium and iodine metabolism for thyroid hormone biosynthesis and human health
Tripeptides restore the number of neuronal spines under conditions of in-vitro-modelled Alzheimers disease
Tirzepatide, another GLP-1 receptor agonist, offers similar results but may have different dosing and effects
In biofeedback training, patients learn how to coordinate muscular activity in the pelvic floor, abdomen, and diaphragm to achieve normal and complete defecation
